{
  "id": "60292e1b1cb411341a000111",
  "type": "yesno",
  "question": "Does Curare function by stimulating the acetylcholine receptor?",
  "ideal_answer": "No. Curare function does not stimulate the acetylcholine receptor.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/8355663",
    "http://www.ncbi.nlm.nih.gov/pubmed/26818254",
    "http://www.ncbi.nlm.nih.gov/pubmed/4351811",
    "http://www.ncbi.nlm.nih.gov/pubmed/11849819",
    "http://www.ncbi.nlm.nih.gov/pubmed/8166227",
    "http://www.ncbi.nlm.nih.gov/pubmed/2479422",
    "http://www.ncbi.nlm.nih.gov/pubmed/21422738",
    "http://www.ncbi.nlm.nih.gov/pubmed/6283380",
    "http://www.ncbi.nlm.nih.gov/pubmed/2713760",
    "http://www.ncbi.nlm.nih.gov/pubmed/25409503",
    "http://www.ncbi.nlm.nih.gov/pubmed/12624651",
    "http://www.ncbi.nlm.nih.gov/pubmed/6308151",
    "http://www.ncbi.nlm.nih.gov/pubmed/16083",
    "http://www.ncbi.nlm.nih.gov/pubmed/10934261",
    "http://www.ncbi.nlm.nih.gov/pubmed/22194270"
  ],
  "snippets": [
    {
      "text": "Usual clinical concentrations of curare cause competitive inhibition of muscle nicotinic acetylcholine receptors while higher concentrations may induce open channel blockade.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11849819",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "nicotinic acetylcholine receptor (nAChR)-blocking agents [e.g., curare or alpha-bungarotoxin (alpha-BTX)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10934261",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The short neurotoxins to which erabutoxins belong act by blocking the nicotinic acetylcholine receptor",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21422738",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Both EFS- and carbachol-evoked contractions of the UES were blocked by curare at a lower concentration than by atropine or hexamethonium, suggesting that the acetylcholine receptor is nicotinic.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12624651",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We applied ACh alone; the nicotinic acetylcholine receptor (nAChR) antagonist curare, either alone or in the presence of ACh; and the muscarinic acetylcholine receptor (mAChR) antagonist atropine, either alone or in the presence of ACh.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26818254",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The EFS-induced contraction of the UES was completely blocked by tetrodotoxin and curare, and abolished in Ca2+ -free Ringer solution.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12624651",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Curare binding and the curare-induced subconductance state of the acetylcholine receptor channel.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/2479422",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We have further investigated this particular mutation by examining the interaction of the competitive antagonist d-tubocurarine (curare) with the receptor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/8355663",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "d-Tubocurarine (curare) is a well-characterized competitive antagonist of nicotinic acetylcholine receptors (AChRs), and it is usually assumed that curare and agonists share a common binding site.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/8166227",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Curare action on nicotinic acetylcholine receptors has a number of facets, of which the best known is competitive antagonism.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/2713760",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The mode of action of curare, a well-known competitive antagonist of acetylcholine at the nicotinic receptor, was examined with the single channel recording technique. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/6308151",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ently, however, it has been shown that curare can also block the channels opened by ACh at the frog neuromuscular junction as well as on rat and Aplysia neurones; moreover, curare is able to depolarize rat myotubes and thus behaves as an agonist for the cholinergic receptor of this preparation (see ref. 6). U",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/6283380",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "One site, competitively blocked by bungarotoxin and by curare, is presumably the acetylcholine receptor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/4351811",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In neuromuscular junction (NMJ) preparations, movements of the muscle must be inhibited if imaging during stimulation is desired (e.g., by application of curare, a potent acetylcholine receptor inhibitor).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22194270",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Curare has long been regarded as a typical competitive antagonist of acetylcholine (ACh) at the vertebrate neuromuscular junction.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/6283380",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Curare inhibition of wild-type receptors is consistent with curare binding to a single high-affinity binding site [inhibitor constant (Ki) = 20 nM].",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/8166227",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Phenylalanine substitution for alpha Y198 [alpha Y198F (notation used here: subunit/amino acid in wild-type/residue number/substitution)] causes a 10-fold increase in curare affinity (Ki = 3.1 nM), and measurement of the recovery from curare inhibition indicates that this increase in affinity is due to a reduction in the rate of curare dissociation from the receptor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/8166227",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "rthermore, sudden increases of research activity are ascribable to historic events, like the first use of curare as muscle relaxant during surgery.DIS",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25409503",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recently, however, it has been shown that curare can also block the channels opened by ACh at the frog neuromuscular junction as well as on rat and Aplysia neurones; moreover, curare is able to depolarize rat myotubes and thus behaves as an agonist for the cholinergic receptor of this preparation (see ref.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/6283380",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In Aplysia nervous tissue, curare appears not to be a specific antagonist for the nicotinic ACh receptor, but rather to be a specific blocking agent for a class of receptor-activated Na+ and Cl- responses.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16083",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The mode of action of curare, a well-known competitive antagonist of acetylcholine at the nicotinic receptor, was examined with the single channel recording technique.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/6308151",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}